⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Hematopoietic Stem Cell Aging (BIRC6 Axis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-23 — Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.: 2026 preclinical study maps a BM Treg → cAMP → PKA → CREB → BIRC6 axis that expands apoptosis-resistant aged HSCs; antibody-conjugated LNP-ASO BIRC6 inhibition rejuvenates hematopoietic output and immune function in middle-aged mice with activity confirmed in middle-aged human HSCs ex vivo — first mechanism-plus-targeted-intervention entry for this page, still fully preclinical. [animal-model] (novelty: 4)
Open questions
Related
Contributing findings
Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.
23-sep-2026
novelty 4
per-area 4
strengthens